Contact Information:
121 South Main Street,
2nd Floor
Providence, RI 02912-G
Box G-S121-2
(401) 863-6790
brunap@brown.edu

Open & Enrolling Clinical Trials

A5251

PROJECT NEW START

A study for people starting new HIV medications, to provide nursing telephone support to enhance adherence.
Key requirements:

  • History of prior HIV combination therapy
  • Difficulty taking anti-HIV medicines as prescribed during the past 12 months
  • Detectable viral load with a genotype while on combination ART within 16 weeks of study entry
  • Viral load equal to or greater than 400 within 90 days of study entry

Contact:
Helen Patterson
401-793-4771 or hpatterson@lifespan.org

A5272

HUMAN PAPILLOMAVIRUS IN ORAL SECTRETIONS

A 48 week study to detect the presence of Human Papillomavirus (HPV) in oral secretions
Key requirements:

  • Must not have taken HIV medications previously
  • Must be ready to begin HIV therapy (either on another study or off study)
  • Viral load of 1000 or greater
  • 18 years of age or older
  • Never received HPV vaccine

Contact:Debbie Perez
401-793-4632 of
dperez@lifespan.org

A5294

HEPATITIS C AND HIV CO-INFECTION STUDY

A 72 week study adding a newly FDA approved drug for Hep C, Boceprevir to standard Hepatitis C treatment. All Hepatitis C drugs will be provided by the study.
Key requirements:

  • Must have both Hepatitis C and HIV
  • 18 years of age or older
  • HIV viral load less than 50,000
  • CD4 count of more than 200
  • Prior treatment for Hepatitis C permissible.

Contact:
Debbie Perez
401-793-4632 or
dperez@lifespan.org

A5298

OPENING SOON

An HPV Vaccine Study for HIV+ men who have sex with men.

This is a new study to show that the HPV vaccination prevents persistent anal infection with HPV types contained in the vaccine. You will get the injections of the HPV vaccine within 24 weeks and followed for 3 to 4 years afterward.
Key requirements:

  • HIV+ men age 27 or older
  • Receptive anal sex within 1 year prior to entry
  • High resolution anoscopy performed withing 45 days prior to entry.
  • Cannot: 1) have history of anal, penile or oropharyngeal cancer, 2) have used topical or surgical treatment for anal neoplasia or warts/condyloma within 6 months prior to entry,
  •  3) have received a prior HPV vaccine

Contact:
Debbie Perez
401-793-4632 or dperez@lifespan.org

SAILING

A new study for people who are HIV positive and treatment resistant

This study is to determine if an investigational HIV drug is safe and effective when used as part of an ART regimen and compare it to Isentress® (raltegravir). Study duration: 48 wks
Key requirements:

  • Resistant to 2 or more HIV drug classes
  • 18 years of age or older
  • Never taken an integrase inhibitor
  • Not pregnant
  • No major liver problems

Contact:
Deborah Perez
401-793-7632 or
dperez@lifespan.org

                                    

VIKING

A new study for people who are HIV positive and currently taking medications including an integrase inhibitor

Key requirements:

  • HIV positive and 18 years of age or older
  • Viral load of 500 or greater
  • Cannot be pregnant, breast feeding, or plan on conceiving (men and women) while on study
  • Currently taking an integrase inhibitor (often called Raltegravir or Isentress)
  • Cannot have moderate or severe liver impairment

Contact:
Helen Patterson
401-793-4771 or hpatterson@lifespan.org

Or

Patricia Delgado
401-793-4769
pdelgado@lifespan.org

FLAMINGO

A two-year study for HIV positive people to determine the safety and effectiveness of an investigational HIV drug (dolutegravir) in people who have never used anti-HIV medications

Key requirements:

  • HIV positive with a viral load of 1000 or greater
  • Never have used HIV medications
  • Not pregnant or planning to become or make someone pregnant
  • Cannot have moderate or severe liver impairment
  • Cannot be planning Hepatitis C treatment during the duration of the study

Contact:
Deborah Perez
401-793-7632 or
dperez@lifespan.org

Or

Patricia Delgado
401-793-4769
pdelgado@lifespan.org

COBI

A one-year (approximate) study for HIV positive adults to determine if an investigational drug Cobicistat (COBI), given with Darunavir  and two other HIV medications is safe and effective in reducing HIV in the blood

Key requirements:

  • 18 years of age or older
  • HIV positive
  • No previous of current use of Darunavir
  • Not being treated for Hepatitis C

Contact:
Helen Patterson
401-793-4771 or hpatterson@lifespan.org

Or

Deborah Perez
401-793-7632 or
dperez@lifespan.org

Enrolling Behavioral Studies

Alcohol & HIV

A 3 year study to look at the effects of alcohol on the brain of people with HIV. Three appointments per year, each lasting from 50 minutes to 2 hours. You will participate in memory, reaction time and cognitive testing, as well as a MRI of the brain.

Key requirements:

  • HIV positive or negative
  • Users and non-users of alcohol
  • Between ages 21 and 70

Contact:
Skye Ross
401-793-4364

Project RAVE

Six session study to investigate the effects of common drugs on mood, behavior and brain activity through magnetic resonance imaging brain scan (MRI).

Key requirements:

  • 21-65 years of age
  • HIV+ and in good health

Contact:
Sarah Park 401-863-6645 or
Skye Ross 401-793-4364